Evaluating Dermatologists' Knowledge of and Attitudes Toward Janus Kinase Inhibitor Therapy for the Treatment of Alopecia Areata
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Ytterberg S, Bhatt D, Mikuls T, Koch G, Fleischmann R, Rivas J
. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386(4):316-326.
DOI: 10.1056/NEJMoa2109927.
View
2.
Tang G, Triwongwaranat D, Sinclair R, Joseph S, Eisman S, Rathnayake D
. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib. Clin Exp Dermatol. 2024; 49(8):875-878.
DOI: 10.1093/ced/llae033.
View
3.
Liu M, Gao Y, Yuan Y, Yang K, Shen C, Wang J
. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2023; 6(6):e2320351.
PMC: 10300710.
DOI: 10.1001/jamanetworkopen.2023.20351.
View
4.
King B, Atanaskova Mesinkovska N, Craiglow B, Kindred C, Ko J, McMichael A
. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. J Am Acad Dermatol. 2021; 86(2):359-364.
DOI: 10.1016/j.jaad.2021.08.043.
View
5.
Needle C, Klein E, Gjonaj J, Nohria A, Karim M, Liu L
. Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: A retrospective analysis. J Am Acad Dermatol. 2023; 90(3):659-662.
PMC: 10922818.
DOI: 10.1016/j.jaad.2023.11.027.
View